Haha! Loved the wet lettuce & heartburn analysis @shooshka. I...

Haha! Loved the wet lettuce & heartburn analysis @shooshka. I was thinking the same thing re the price query from last Friday, ie will this affect us in anyway this week, on any news?

Disclosure to the market is a thing for compliance too, & after @Hotdog11’s comments, which may well be the case to some extent with massive buying, as in a buy recommendation. I’m not convinced that was the whole story.

PIQ & SH know news is fairly imminent, we are almost 2/3 the way through Feb already, so much closer from recent ANNs.

I think it was a very valid comment that @katy made in regards to coordination & timing of ANNs, especially with another publicly listed company (Janssen/Johnson & Johnson) & OS based, however a big presence globally including here in Australia.

Our SP has been up & down like a roller coaster ride lately, & sometimes I truly wonder if stop losses are so helpful in LT holds on biotechs? That almost appears like it’s being manipulated here & the next thing you know SP up again (not just once, multiple times).

I’m sure many will be happy we are sitting in the low 30s again. I agree with Eqz & others, on the race to 50c late 2018 & some good news here soon, it will run again.

I am hoping for some really solid news soon, it’s been a long wait on this clinical trial with Janssen, we have been given some pretty clear clues of benefits of a positive outcome, plus all the other analytics & pipeline for PIQ.

The global need for this predictive testing with PromarkerD, we are not totally reliant on Pharma, as we have CE Mark in Europe (that’s a big thing) already & it has already been clinically validated in previous trials & a partnership for mass spectrometry in EU, plus the validation of ELISA test kits.

If you haven’t already, have a read of the latest global statistics on chronic kidney disease (all types), and bearing in mind this was only data up until 2017, & funded by the Bill & Melinda Gates Foundation, so you can rest assured that all this work by WHO, Not for Profits, & the Academic community; have brought to their attention a huge global unmet clinical need. They only invest in this kind of thing. HIV, TB, gastro-intestinal diseases affecting developing countries (Giardia is a very common one that PIQ are working on), malaria. CKD is up there. Scroll to discussion if you don’t have time, but it was a huge global research collaboration & if you go to the end, you will see all the contributors & extra grants to help with this, including Australia. There is also an excellent reference list for research.

Not everything was covered in that ASX response, but totally on the ball with that.

Just going with the flow on my kidney disease stocks, as I have been for a long time, for various reasons. Totally the wrong time to get frustrated now I believe & others can help you make that happen. Just believe in what you do & WHY. I guess that’s all I can say, & many will not agree, but it will take something very evident & substantial to change my mind here. That has never happened. GLTAH